Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8102975rdf:typepubmed:Citationlld:pubmed
pubmed-article:8102975lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:8102975lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8102975lifeskim:mentionsumls-concept:C0060608lld:lifeskim
pubmed-article:8102975lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8102975lifeskim:mentionsumls-concept:C0070651lld:lifeskim
pubmed-article:8102975lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:8102975pubmed:issue1lld:pubmed
pubmed-article:8102975pubmed:dateCreated1993-9-28lld:pubmed
pubmed-article:8102975pubmed:abstractTextThe effects of intrathecal injections of F8Famide (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2, 0.05-17.5 nmol) and FMRF-amide (Phe-Met-Arg-Phe-NH2, 0.002-25 nmol), known as anti-opioid agents, were investigated by using noxious thermal (tail flick) and mechanical (paw pressure) tests in the rat. Both peptides produced significant long-lasting (24-48 h) analgesia in both tests without causing detectable motor dysfunction. Pretreatment with systemic naloxone (5.5 mumol/kg i.p.) attenuated the initial antinociceptive effects (first hour) induced by both peptides (8.8 nmol) in the tail flick test and only by FMRFamide in the paw pressure test. A subeffective dose of F8Famide (0.05 nmol) enhanced both the intensity and the duration of spinal morphine (6.6 nmol) analgesia in both tests. In contrast, a subanalgesic dose of FMRFamide (0.002 nmol) decreased the intensity and enhanced the duration of the effect of morphine. These results show that, besides acting as antinociceptive agents in the spinal cord, F8Famide and FMRFamide could differentially modulate spinal opioid functions.lld:pubmed
pubmed-article:8102975pubmed:languageenglld:pubmed
pubmed-article:8102975pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:citationSubsetIMlld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102975pubmed:statusMEDLINElld:pubmed
pubmed-article:8102975pubmed:monthJunlld:pubmed
pubmed-article:8102975pubmed:issn0014-2999lld:pubmed
pubmed-article:8102975pubmed:authorpubmed-author:ZajacJ MJMlld:pubmed
pubmed-article:8102975pubmed:authorpubmed-author:JhamandasKKlld:pubmed
pubmed-article:8102975pubmed:authorpubmed-author:SutakMMlld:pubmed
pubmed-article:8102975pubmed:authorpubmed-author:GouardèresCClld:pubmed
pubmed-article:8102975pubmed:issnTypePrintlld:pubmed
pubmed-article:8102975pubmed:day11lld:pubmed
pubmed-article:8102975pubmed:volume237lld:pubmed
pubmed-article:8102975pubmed:ownerNLMlld:pubmed
pubmed-article:8102975pubmed:authorsCompleteYlld:pubmed
pubmed-article:8102975pubmed:pagination73-81lld:pubmed
pubmed-article:8102975pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:meshHeadingpubmed-meshheading:8102975-...lld:pubmed
pubmed-article:8102975pubmed:year1993lld:pubmed
pubmed-article:8102975pubmed:articleTitleAntinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat.lld:pubmed
pubmed-article:8102975pubmed:affiliationLaboratoire de Pharmacologie et de Toxicologie Fondamentales, CNRS, Toulouse, France.lld:pubmed
pubmed-article:8102975pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8102975pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8102975pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8102975lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8102975lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8102975lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8102975lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8102975lld:pubmed